FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987208829> ?p ?o ?g. }

• W1987208829 endingPage "631" @default.
• W1987208829 startingPage "623" @default.
• W1987208829 abstract "Study objective To determine the demographic, clinical, and radiographic characteristics of corticosteroid-treated patients with sarcoidosis who developed relapse following a period of clinical stability lasting longer than 1 month, and to compare these characteristics with those of a group of patients with sarcoidosis who were not treated. Design Historic, concurrent and prospective, nonrandomized, observational study. Setting Ambulatory sarcoidosis clinic in a university city hospital. Patients Over a 4-year calendar period, 337 patients with sarcoidosis were prospectively enrolled in a registry. One hundred eighteen patients were assigned to a spontaneous remission group when symptoms resolved without treatment, and 103 were assigned to an induced remission group when symptoms resolved following corticosteroid therapy and successful discontinuation. In 116 patients assigned to a recalcitrant group, therapy could not be stopped for 1 month or more owing to severity of symptoms or lack of compliance. We defined relapse as a recurrence of symptoms of sufficient severity to warrant treatment with corticosteroids, following a remission without treatment lasting greater than 1 month. Intervention Patients who were judged to be sufficiently symptomatic to preclude observation without treatment or who failed to respond to conservative treatment with topical or inhaled corticosteroids or nonsteroidal anti-inflammatory agents were treated with systemic corticosteroids at a target dose of 20 mg prednisone per day for 1 year. Measurements and results We observed a 74% relapse rate in the induced remission group, but only an 8% relapse rate in the spontaneous remission group (p<0.01). Relapse occurred with similar frequency in whites and African-Americans (20% vs 28%), despite a lower treatment rate in white patients than in African-Americans (43% vs 76%; p<0.01). White patients maintained a sustained remission with twice the frequency of African-Americans (58% vs 29%; p<0.01). During relapse, 40% of chest radiographs showed no change in type, but there was a significant increase in interstitial profusion (p<0.05). Initial presentation with asymptomatic chest radiographic abnormalities, erythema nodosum, or peripheral adenopathy portended a favorable prognosis, with sustained remission in 60% of such patients lasting 130 ± 226 months from time of diagnosis. In contrast, patients who presented with musculoskeletal complaints were nine times, and those with symptoms from hepatic involvement were three times more likely to suffer relapse than to sustain remission without receiving corticosteroids. Most relapses (50%) occurred between 2 and 6 months after discontinuing steroid therapy, but late relapse was not unusual, occurring more than 12 months after discontinuing steroid therapy in 20% of patients with induced remission. Conclusions Relapse occurred frequently in patients with sarcoidosis who had been treated with corticosteroids, and rarely occurred in patients who had not been treated with corticosteroids in the past. The striking difference in relapse rate between treated and untreated patients suggests that patients with disease that would later be severe and protracted were almost unerringly identified early in their course. One explanation is that severe presenting symptoms portend a protracted and recurrent course; an alternative explanation is that corticosteroids contributed to the prolongation of the disease by delaying resolution. To determine the demographic, clinical, and radiographic characteristics of corticosteroid-treated patients with sarcoidosis who developed relapse following a period of clinical stability lasting longer than 1 month, and to compare these characteristics with those of a group of patients with sarcoidosis who were not treated. Historic, concurrent and prospective, nonrandomized, observational study. Ambulatory sarcoidosis clinic in a university city hospital. Over a 4-year calendar period, 337 patients with sarcoidosis were prospectively enrolled in a registry. One hundred eighteen patients were assigned to a spontaneous remission group when symptoms resolved without treatment, and 103 were assigned to an induced remission group when symptoms resolved following corticosteroid therapy and successful discontinuation. In 116 patients assigned to a recalcitrant group, therapy could not be stopped for 1 month or more owing to severity of symptoms or lack of compliance. We defined relapse as a recurrence of symptoms of sufficient severity to warrant treatment with corticosteroids, following a remission without treatment lasting greater than 1 month. Patients who were judged to be sufficiently symptomatic to preclude observation without treatment or who failed to respond to conservative treatment with topical or inhaled corticosteroids or nonsteroidal anti-inflammatory agents were treated with systemic corticosteroids at a target dose of 20 mg prednisone per day for 1 year. We observed a 74% relapse rate in the induced remission group, but only an 8% relapse rate in the spontaneous remission group (p<0.01). Relapse occurred with similar frequency in whites and African-Americans (20% vs 28%), despite a lower treatment rate in white patients than in African-Americans (43% vs 76%; p<0.01). White patients maintained a sustained remission with twice the frequency of African-Americans (58% vs 29%; p<0.01). During relapse, 40% of chest radiographs showed no change in type, but there was a significant increase in interstitial profusion (p<0.05). Initial presentation with asymptomatic chest radiographic abnormalities, erythema nodosum, or peripheral adenopathy portended a favorable prognosis, with sustained remission in 60% of such patients lasting 130 ± 226 months from time of diagnosis. In contrast, patients who presented with musculoskeletal complaints were nine times, and those with symptoms from hepatic involvement were three times more likely to suffer relapse than to sustain remission without receiving corticosteroids. Most relapses (50%) occurred between 2 and 6 months after discontinuing steroid therapy, but late relapse was not unusual, occurring more than 12 months after discontinuing steroid therapy in 20% of patients with induced remission. Relapse occurred frequently in patients with sarcoidosis who had been treated with corticosteroids, and rarely occurred in patients who had not been treated with corticosteroids in the past. The striking difference in relapse rate between treated and untreated patients suggests that patients with disease that would later be severe and protracted were almost unerringly identified early in their course. One explanation is that severe presenting symptoms portend a protracted and recurrent course; an alternative explanation is that corticosteroids contributed to the prolongation of the disease by delaying resolution." @default.
• W1987208829 created "2016-06-24" @default.
• W1987208829 creator A5005346049 @default.
• W1987208829 creator A5009896540 @default.
• W1987208829 creator A5011236147 @default.
• W1987208829 creator A5054434827 @default.
• W1987208829 creator A5056044861 @default.
• W1987208829 date "1997-03-01" @default.
• W1987208829 modified "2023-09-29" @default.
• W1987208829 title "Outcome in Sarcoidosis" @default.
• W1987208829 cites W1673003485 @default.
• W1987208829 cites W1924611011 @default.
• W1987208829 cites W1988497385 @default.
• W1987208829 cites W2032943095 @default.
• W1987208829 cites W2035562385 @default.
• W1987208829 cites W2074760059 @default.
• W1987208829 cites W2147469461 @default.
• W1987208829 cites W2162198836 @default.
• W1987208829 doi "https://doi.org/10.1378/chest.111.3.623" @default.
• W1987208829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9118698" @default.
• W1987208829 hasPublicationYear "1997" @default.
• W1987208829 type Work @default.
• W1987208829 sameAs 1987208829 @default.
• W1987208829 citedByCount "272" @default.
• W1987208829 countsByYear W19872088292012 @default.
• W1987208829 countsByYear W19872088292013 @default.
• W1987208829 countsByYear W19872088292014 @default.
• W1987208829 countsByYear W19872088292015 @default.
• W1987208829 countsByYear W19872088292016 @default.
• W1987208829 countsByYear W19872088292017 @default.
• W1987208829 countsByYear W19872088292018 @default.
• W1987208829 countsByYear W19872088292019 @default.
• W1987208829 countsByYear W19872088292020 @default.
• W1987208829 countsByYear W19872088292021 @default.
• W1987208829 countsByYear W19872088292022 @default.
• W1987208829 countsByYear W19872088292023 @default.
• W1987208829 crossrefType "journal-article" @default.
• W1987208829 hasAuthorship W1987208829A5005346049 @default.
• W1987208829 hasAuthorship W1987208829A5009896540 @default.
• W1987208829 hasAuthorship W1987208829A5011236147 @default.
• W1987208829 hasAuthorship W1987208829A5054434827 @default.
• W1987208829 hasAuthorship W1987208829A5056044861 @default.
• W1987208829 hasConcept C126322002 @default.
• W1987208829 hasConcept C141071460 @default.
• W1987208829 hasConcept C188816634 @default.
• W1987208829 hasConcept C23131810 @default.
• W1987208829 hasConcept C2776804153 @default.
• W1987208829 hasConcept C2778715236 @default.
• W1987208829 hasConcept C2778720950 @default.
• W1987208829 hasConcept C2781301800 @default.
• W1987208829 hasConcept C35785553 @default.
• W1987208829 hasConcept C71924100 @default.
• W1987208829 hasConceptScore W1987208829C126322002 @default.
• W1987208829 hasConceptScore W1987208829C141071460 @default.
• W1987208829 hasConceptScore W1987208829C188816634 @default.
• W1987208829 hasConceptScore W1987208829C23131810 @default.
• W1987208829 hasConceptScore W1987208829C2776804153 @default.
• W1987208829 hasConceptScore W1987208829C2778715236 @default.
• W1987208829 hasConceptScore W1987208829C2778720950 @default.
• W1987208829 hasConceptScore W1987208829C2781301800 @default.
• W1987208829 hasConceptScore W1987208829C35785553 @default.
• W1987208829 hasConceptScore W1987208829C71924100 @default.
• W1987208829 hasIssue "3" @default.
• W1987208829 hasLocation W19872088291 @default.
• W1987208829 hasLocation W19872088292 @default.
• W1987208829 hasOpenAccess W1987208829 @default.
• W1987208829 hasPrimaryLocation W19872088291 @default.
• W1987208829 hasRelatedWork W2023217227 @default.
• W1987208829 hasRelatedWork W2044576232 @default.
• W1987208829 hasRelatedWork W2053310824 @default.
• W1987208829 hasRelatedWork W2091322101 @default.
• W1987208829 hasRelatedWork W2137075480 @default.
• W1987208829 hasRelatedWork W2160818737 @default.
• W1987208829 hasRelatedWork W2394621672 @default.
• W1987208829 hasRelatedWork W2409499200 @default.
• W1987208829 hasRelatedWork W2412931861 @default.
• W1987208829 hasRelatedWork W56598467 @default.
• W1987208829 hasVolume "111" @default.
• W1987208829 isParatext "false" @default.
• W1987208829 isRetracted "false" @default.
• W1987208829 magId "1987208829" @default.
• W1987208829 workType "article" @default.